Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
D. Whyte, J. Vande Voorde, D. Sumpton, S. Dhayade, E. Dornier, M. Moore, D. Novo, J. Peters, R. Wiesheu, J. B. Mackey, A. J. McFarlane, F. Fercoq, S. Fisher, C. Dehesa Caballero, K. Gilroy, , C. J. Clarke
bioRxiv · Jul 2, 2024 · PreprintCancer Biology
J. A. Waldron, G. Kanellos, R. C. L. Smith, J. R. P. Knight, J. Munro, C. Alexandrou, N. Vlahov, L. Pardo-Fernandez, M. Moore, S. L. Gillen, D. Strathdee, D. Stevenson, F. C. Warrander, K. Gilroy, C. Nixon, , O. J. Sansom
This study shows eIF4A1 is critical for supporting translational demands in Wnt-driven colorectal cancers, while eIF4A2 loss accelerates tumourigenesis, and eFT226 inhibits eIF4A1 function in these models.
bioRxiv · Nov 10, 2023 · PreprintCancer Biology
A. K. Najumudeen, S. K. Fey, L. M. Millet, C. A. Ford, K. Gilroy, N. Gunduz, R. A. Ridgway, E. Anderson, D. Strathdee, W. Clark, C. Nixon, J. P. Morton, A. D. Campbell, O. J. Sansom
This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.
bioRxiv · Aug 29, 2023 · PreprintCancer Biology
M. Moore, L. Pardo, L. Mitchell, T. Schmidt, J. Waldron, S. May, M. Mueller, R. Smith, D. Strathdee, S. Bryson, K. Hodge, S. Lilla, A. Wilczynska, L. McGarry, S. Gillen, , J. C. Norman
The paper shows that eIF4A2, a negative regulator of mRNA translation, promotes ECM deposition to accelerate HCC initiation by influencing integrin-mediated signaling and senescence exit.
bioRxiv · Aug 16, 2023 · PreprintCancer Biology
S. Laing, B. Kruspig, R. Shaw, L. Officer-Jones, S. Edwards, D. McKinven, Y.-C. Hsieh, I. Powley, N. Brady, R. Pennie, R. Kwan, A. Lima, S. Myrta, M. Periyasamy, I. C. Dye, , D. J. Murphy
The paper investigates how ERBB signaling contributes to immune evasion in KRAS-driven lung adenocarcinoma using a novel mouse model and finds that transient ERBB blockade can restore immune surveillance when combined with PD1 blockade.
bioRxiv · Jul 24, 2023 · PreprintCancer Biology